92PVall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI). (23rd October 2018) - Hierro, C; Matos, I; Martin-Liberal, J; Ochoa De Olza Amat, M; Felip, E; Costa Rivas, M; Vieito Villar, M; Brana, I; Azaro, A; Perez-Gago, M C; Gros, A; Carles, J; et al.